|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGF |
Gene summary for PIGF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGF | Gene ID | 5281 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class F | |
| Gene Alias | OORS | |
| Cytomap | 2p21 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q07326 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5281 | PIGF | LZE2T | Human | Esophagus | ESCC | 1.09e-07 | 5.14e-01 | 0.082 |
| 5281 | PIGF | LZE4T | Human | Esophagus | ESCC | 8.59e-11 | 3.88e-01 | 0.0811 |
| 5281 | PIGF | LZE5T | Human | Esophagus | ESCC | 2.08e-02 | 1.28e-01 | 0.0514 |
| 5281 | PIGF | LZE8T | Human | Esophagus | ESCC | 9.69e-04 | 2.53e-01 | 0.067 |
| 5281 | PIGF | LZE20T | Human | Esophagus | ESCC | 1.19e-03 | 1.87e-01 | 0.0662 |
| 5281 | PIGF | LZE22T | Human | Esophagus | ESCC | 1.53e-07 | 7.03e-01 | 0.068 |
| 5281 | PIGF | LZE24T | Human | Esophagus | ESCC | 1.21e-13 | 2.73e-01 | 0.0596 |
| 5281 | PIGF | LZE21T | Human | Esophagus | ESCC | 1.41e-03 | 3.35e-01 | 0.0655 |
| 5281 | PIGF | LZE6T | Human | Esophagus | ESCC | 5.27e-06 | 3.30e-01 | 0.0845 |
| 5281 | PIGF | P1T-E | Human | Esophagus | ESCC | 4.88e-07 | 3.21e-01 | 0.0875 |
| 5281 | PIGF | P2T-E | Human | Esophagus | ESCC | 2.26e-27 | 4.80e-01 | 0.1177 |
| 5281 | PIGF | P4T-E | Human | Esophagus | ESCC | 8.29e-33 | 7.30e-01 | 0.1323 |
| 5281 | PIGF | P5T-E | Human | Esophagus | ESCC | 2.70e-18 | 3.28e-01 | 0.1327 |
| 5281 | PIGF | P8T-E | Human | Esophagus | ESCC | 1.46e-24 | 4.76e-01 | 0.0889 |
| 5281 | PIGF | P9T-E | Human | Esophagus | ESCC | 1.18e-18 | 4.73e-01 | 0.1131 |
| 5281 | PIGF | P10T-E | Human | Esophagus | ESCC | 2.34e-30 | 5.45e-01 | 0.116 |
| 5281 | PIGF | P11T-E | Human | Esophagus | ESCC | 2.64e-13 | 5.14e-01 | 0.1426 |
| 5281 | PIGF | P12T-E | Human | Esophagus | ESCC | 4.43e-43 | 7.09e-01 | 0.1122 |
| 5281 | PIGF | P15T-E | Human | Esophagus | ESCC | 2.01e-33 | 8.44e-01 | 0.1149 |
| 5281 | PIGF | P16T-E | Human | Esophagus | ESCC | 2.21e-32 | 6.16e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00065063 | Esophagus | ESCC | GPI anchor biosynthetic process | 26/8552 | 32/18723 | 3.97e-05 | 3.21e-04 | 26 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00065053 | Esophagus | ESCC | GPI anchor metabolic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:00066642 | Esophagus | ESCC | glycolipid metabolic process | 63/8552 | 100/18723 | 3.55e-04 | 2.06e-03 | 63 |
| GO:19035092 | Esophagus | ESCC | liposaccharide metabolic process | 63/8552 | 101/18723 | 5.25e-04 | 2.90e-03 | 63 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:0009247 | Esophagus | ESCC | glycolipid biosynthetic process | 42/8552 | 68/18723 | 5.48e-03 | 2.05e-02 | 42 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:0042158 | Liver | Cirrhotic | lipoprotein biosynthetic process | 36/4634 | 96/18723 | 3.69e-03 | 2.03e-02 | 36 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005632 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa0056311 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGF | SNV | Missense_Mutation | novel | c.486C>A | p.Ser162Arg | p.S162R | Q07326 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIGF | SNV | Missense_Mutation | novel | c.47G>A | p.Cys16Tyr | p.C16Y | Q07326 | protein_coding | tolerated(0.14) | possibly_damaging(0.793) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PIGF | SNV | Missense_Mutation | novel | c.460N>G | p.Ser154Gly | p.S154G | Q07326 | protein_coding | tolerated(0.21) | benign(0.334) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PIGF | SNV | Missense_Mutation | novel | c.628A>C | p.Asn210His | p.N210H | Q07326 | protein_coding | tolerated(0.59) | benign(0.015) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PIGF | SNV | Missense_Mutation | novel | c.96N>T | p.Glu32Asp | p.E32D | Q07326 | protein_coding | tolerated(0.56) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| PIGF | SNV | Missense_Mutation | novel | c.550N>G | p.Trp184Gly | p.W184G | Q07326 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PIGF | SNV | Missense_Mutation | c.263N>G | p.Leu88Arg | p.L88R | Q07326 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PIGF | SNV | Missense_Mutation | c.263N>G | p.Leu88Arg | p.L88R | Q07326 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| PIGF | SNV | Missense_Mutation | c.235G>A | p.Gly79Arg | p.G79R | Q07326 | protein_coding | tolerated(1) | benign(0) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGF | SNV | Missense_Mutation | novel | c.21G>T | p.Lys7Asn | p.K7N | Q07326 | protein_coding | deleterious(0.01) | benign(0.075) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5281 | PIGF | DRUGGABLE GENOME | antibody | ZALTRAP | ZALTRAP | |
| 5281 | PIGF | DRUGGABLE GENOME | antibody | ZIV-AFLIBERCEPT | AFLIBERCEPT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |